Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma

In a multicenter study, researchers investigated the prognostic value of absolute lymphocyte count (ALC) in the first 15 days after CAR-T infusion in patients with relapsed multiple myeloma treated with ciltacabtagene autoleucel and idecabtagene vicleucel. They found that patients with higher maximum ALC had better depth of response, progression-free survival, and duration of response.